Pyxis Oncology (NASDAQ:PYXS - Get Free Report) posted its earnings results on Saturday. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.19, Yahoo Finance reports. The business had revenue of $16.15 million for the quarter, compared to the consensus estimate of $4.25 million.
Pyxis Oncology Stock Performance
Shares of PYXS stock traded up $0.01 during midday trading on Wednesday, hitting $4.21. 363,414 shares of the company were exchanged, compared to its average volume of 733,222. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The firm has a market capitalization of $247.88 million, a P/E ratio of -2.30 and a beta of 1.45. The firm's 50 day moving average price is $4.79 and its two-hundred day moving average price is $3.48.
Wall Street Analyst Weigh In
PYXS has been the topic of several recent analyst reports. SVB Leerink started coverage on Pyxis Oncology in a report on Tuesday, January 23rd. They set an "outperform" rating and a $12.00 price objective on the stock. Jefferies Financial Group reissued a "buy" rating and set a $10.00 price target on shares of Pyxis Oncology in a research report on Tuesday, May 7th. BTIG Research began coverage on Pyxis Oncology in a research note on Friday, February 9th. They issued a "buy" rating and a $8.00 price target for the company. Leerink Partnrs reiterated an "outperform" rating on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Friday, March 22nd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $8.80.
Read Our Latest Stock Analysis on PYXS
About Pyxis Oncology
(
Get Free Report)
Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.
See Also
Before you consider Pyxis Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.
While Pyxis Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
